Publications
Peer-Reviewed Manuscripts
- Distinct inactivated bacterial-based immune modulators vary in their therapeutic efficacies for treating disease based on the organ site of pathology.
- Novel Microbial-Based Immunotherapy Approach for Crohn’s Disease.
- Immune Stimulation Using a Gut Microbe-Based Immunotherapy Reduces Disease Pathology and Improves Barrier Function in Ulcerative Colitis.
- Harnessing innate lung anti-cancer effector functions with a novel bacterial-derived immunotherapy.
- Attenuating immune pathology using a microbial-based intervention in a mouse model of cigarette smoke-induced lung inflammation.
- A novel microbe-based treatment that attenuates the inflammatory profile in a mouse model of allergic airway disease.
- Site-Specific Immunomodulator: A Novel Treatment for Crohn’s Disease.
Select Scientific Abstracts and Presentations
- Novel microbial-based immunotherapy approach enables application of adoptive cell therapy for solid tumors by enhancing both immune access to tumor microenvironment and cancer cell immunogenecity. International Cancer Immunotherapy Conference (CICON) 2019, Paris, France. Poster Presentation
- Novel Escherichia coli Derived Therapeutic Immunotherapies Reduce Innate Immune Responses to Protect Muc2 deficient mice from Spontaneous Colitis. International Congress of Mucosal Immunology 2017, Washington DC. Talk and Poster Presentation
- Site-Specific Immunomodulators exploit the potent immune response to infection to effectively mobilize innate anti-tumour immunity. BioCanRx Summit for Cancer Immunotherapy 2017, Gatineau, QC. Poster Presentation
- Harnessing innate anti-tumour immunity using a Klebsiella-derived therapeutic to reduce tumour burden and improve outcomes in mouse models of lung cancer. American Association of Immunologists – Immunology 2017, Washington DC. Talk & Poster Presentation
- A Phase 1/2 Randomized, Placebo-Controlled, Double-Blind Study of the Induction of Clinical Response and Remission Using a Novel Immunotherapy (QBECO) in Subjects with Moderate To Severe Crohn’s Disease. Digestive Diseases Week 2017, Chicago IL. Poster Presentation
- Site-Specific Immunomodulators (SSIs) are Novel Immunotherapies for Cancer, The American Association of Immunologists Immunology 2016, Seattle, WA. Poster Presentation
- Clinical Trial Recruitment with Social Media – What to Expect?, Digestive Diseases Week 2016, San Diego, CA, Poster Presentation
- Anti-cancer Efficacy in a Preclinical Model of Lung Cancer Using QBKPN Site-Specific Immunomodulation, Keystone Symposia 2016, Killarney, Ireland, Poster Presentation
- Site Specific Immunomodulators (SSIs): A Novel Immunotherapy for Cancer, Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015, Vancouver, BC, Poster Presentation
- Anti-cancer Efficacy in a Preclinical Model of Lung Cancer Using QBKPN Site Specific Immunomodulation, Canadian Cancer Immunotherapy Consortium (CCIC) Symposium 2015, Vancouver, BC, Poster Presentation
- Site Specific Immunomodulation – A Novel Therapeutic Approach for the Management of Moderate-to-Severe Crohn’s Disease, Digestive Diseases Week 2014, Chicago, Illinois, Poster Presentation